Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Schedules Meetings On Plastic Surgery Devices, Ophthalmic Dispensers

Executive Summary

The General and Plastic Surgery Devices Panel of the Medical Devices Advisory Committee will meet from 26-27 October, and the Ophthalmic Devices Panel of the Medical Devices Advisory Committee will meet 10 November. 

You may also be interested in...

Ophthalmic Dispensers Recommended Class I Designation By FDA Panel

The FDA’s Ophthalmic Devices Panel approved a Class I designation for ophthalmic dispensers, which were reclassified from drugs to devices after the Genus v. FDA decision.

Medtech Connect Episode 6: The Latest And Greatest In Digital Health Regulations

In this episode, Medtech Insight regulatory reporter Hannah Daniel speaks to Erez Kaminski, CEO and founder of Ketryx, which assists clients in creating FDA-regulated software. He updates us on the latest and greatest in digital health regulations, including PCCPs, decentralized clinical trials, and AI/ML software. We talk about some of the challenges and opportunities that often arise from these regulations, and Kaminski shares a personal story about why the safety of medical devices matters so much to him.

FTC Health Breach Notification Amendments Underscore Need For Federal Legislation, Expert Says

Former deputy privacy director of HHS Deven McGraw spoke to Medtech Insight about the shortfalls of the FTC’s proposed health breach notification amendments.


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts